41010-49-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-2-phenylamino-pyridine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex molecular structures that can target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Amino-2-phenylamino-pyridine is utilized as a component in the development of compounds that can protect crops from pests and diseases, leveraging its reactive groups to form stable and effective agrochemical products.
Used in Dye Industry:
3-Amino-2-phenylamino-pyridine is employed as a building block in the production of dyes due to its capacity to form colored compounds that are stable and have specific absorption properties, which are crucial for various applications in coloring textiles, plastics, and other materials.
Used in Corrosion Inhibition:
3-Amino-2-phenylamino-pyridine is used as a corrosion inhibitor for metals to protect them from environmental degradation, capitalizing on its chemical structure to form a protective layer on metal surfaces and reduce oxidation.
Used in Research and Development:
In research settings, 3-Amino-2-phenylamino-pyridine is explored for its potential anti-cancer and anti-inflammatory properties, with ongoing studies aiming to understand its mechanisms of action and therapeutic potential in treating various diseases and conditions.

InChI:InChI=1/C11H11N3/c12-10-7-4-8-13-11(10)14-9-5-2-1-3-6-9/h1-8H,12H2,(H,13,14)

Upstream product

• 6298-19-7 2-chloro-3-aminopyridine 
• 62-53-3 aniline 
• 34949-41-2 3-nitro-2-phenylaminopyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 462-08-8 pyridin-3-ylamine 

Downstream Products

• 61532-33-0 1-phenylimidazolo<5,4-b>pyridine 
• 41231-01-0 1-phenyl-2-methylimidazolo<5,4-b>pyridine 
• 1333931-05-7 C₁₃H₉N₃O₂*ClH 
• 1333931-13-7 C₂₀H₁₄FN₅O 
• 1333931-14-8 C₂₄H₁₇N₅O₂ 
• 1333931-15-9 C₂₁H₁₇N₅O₃ 
• 1333931-16-0 C₁₈H₁₄N₆O 
• 1333931-17-1 C₂₂H₁₆N₆O 
• 1333931-18-2 C₂₃H₂₁N₅O₄ 
• 1333931-19-3 C₂₀H₁₄N₆O₃ 
• 1333931-06-8 C₁₃H₈ClN₃O*ClH 
• 1333931-07-9 2-hydrazinyl-4-phenylpyrido[2,3-b]pyrazin-3(4H)-one 
• 1311465-59-4 2-N-phenylamino-3-N-isopropylaminopyridine 
• 1393176-71-0 [(S)-1-(2-phenylaminopyridin-3-ylcarbamoyl)propyl]carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Novel imidazo[4,5-b]pyridine derived acrylonitriles: A combined experimental and computational study of their antioxidative potential

We describe the synthesis of novel unsubstituted and N-substituted imidazo[4,5-b]pyridine derived acrylonitriles, which were prepared by classical and microwave assisted organic synthesis. Their antioxidative potential was studied using spectroscopic DPPH

Heterocyclic compound and organic light emitting device including the same

Provided are a heterocyclic compound and an organic light-emitting device including the same. The heterocyclic compound may be represented by Formula 1: in the Formula 1, A1, X2, Y1, Y2, m1, m2, R10,R20, R30, b10, b20 and b30 are same as described in the description.

Platinum compound with photoluminescence performance and preparation method thereof

The invention belongs to the technical field of organic complex synthesis, and particularly relates to a platinum compound with photoluminescence performance and a preparation method thereof. The molecular formula of the platinum compound with the photolu

Pt (II) photoluminescence compound based on pyridinoimidazole derivative and preparation method thereof

The invention belongs to the technical field of synthesis of organic complexes, and particularly relates to a Pt (II) photoluminescence compound based on a pyridinoimidazole derivative and a preparation method thereof. The molecular formula of the Pt (II)

Platinum luminescent compound based on pyridinoimidazole derivative and preparation method of platinum luminescent compound

The invention belongs to the technical field of synthesis of organic complexes, and particularly relates to a platinum luminescent compound based on a pyridinoimidazole derivative and a preparation method of the platinum luminescent compound. The molecula

Synthesis and biological evaluation of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides as antimitotic agents

A library of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides (7a–al) have been designed, synthesized and screened for their anti-proliferative activity against some selected human cancer cell lines namely DU-145, A-549, MCF-7 and HeLa. Most of them have shown promising cytotoxicity against lung cancer cell line (A549), amongst them 7f was found to be the most potent anti-proliferative congener. Furthermore, 7f exhibited comparable tubulin polymerization inhibition (IC50 value 2.04 μM) to the standard E7010 (IC50 value 2.15 μM). Moreover, flow cytometric analysis revealed that this compound induced apoptosis via cell cycle arrest at G2/M phase in A549 cells. Induction of apoptosis was further observed by examining the mitochondrial membrane potential and was also confirmed by Hoechst staining as well as Annexin V-FITC assays. Furthermore, molecular docking studies indicated that compound 7f binds to the colchicine binding site of the β-tubulin. Thus, 7f exhibits anti-proliferative properties by inhibiting the tubulin polymerization through the binding at the colchicine active site and by induction of apoptosis.

Rational design and synthesis of 2-anilinopyridinyl-benzothiazole Schiff bases as antimitotic agents

Based on our previous results and literature precedence, a series of 2-anilinopyridinyl-benzothiazole Schiff bases were rationally designed by performing molecular modeling experiments on some selected molecules. The binding energies of the docked molecules were better than the E7010, and the Schiff base with trimethoxy group on benzothiazole moiety, 4y was the best. This was followed by the synthesis of a series of the designed molecules by a convenient synthetic route and evaluation of their anticancer potential. Most of the compounds have shown significant growth inhibition against the tested cell lines and the compound 4y exhibited good antiproliferative activity with a GI50 value of 3.8?μM specifically against the cell line DU145. In agreement with the docking results, 4y exerted cytotoxicity by the disruption of the microtubule dynamics by inhibiting tubulin polymerization via effective binding into colchicine domain, comparable to E7010. Detailed binding modes of 4y with colchicine binding site of tubulin were studied by molecular docking. Furthermore, 4y induced apoptosis as evidenced by biological studies like mitochondrial membrane potential, caspase-3, and Annexin V-FITC assays.

Synthesis of 2-anilinopyridine dimers as microtubule targeting and apoptosis inducing agents

A series of 2-anilinopyridine dimers have been synthesized and evaluated for their anticancer potential. Most of the compounds have showed significant growth inhibition of the cell lines tested and compound 4d was most effective amongst the series display

Synthesis and cytotoxicity studies of novel 2-hydrazonylpyrido[2,3-b] pyrazin-3(4H)-ones

In an attempt to develop potent antitumor agents, a series of novel 2-hydrazonylpyrido[2,3-b]pyrazin-3(4H)-one derivatives were designed and synthesized. All the prepared compounds were screened for their cytotoxic activities against A549, MDA-MB-231 and HT-29 cell lines in vitro. Pharmacological data indicated that five of the target compounds showed cytotoxicity against A549 cell line below a concentration of 1 μM. Compound 15g was the most potent one with IC50 values of 0.19, 2.11 and 2.15 μM against A549, MDA-MB-231 and HT29 cell lines, respectively. A series of 2-hydrazonylpyrido[2,3-b]pyrazin-3(4H)-one derivatives was designed and synthesized. Preliminary structure-activity relationships suggested that compounds with 4-methoxyphenyl or 4-(trifluoromethoxy)phenyl groups on the N-4 position were generally more potent than those with an unsubstituted phenyl group. Copyright

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.